XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has signed a nonbinding letter of intent (“LOI”) with a U.S.-based thin film manufacturing firm. The collaboration between the two companies will focus on evaluating potential business synergies for manufacturing, import/export, distribution and product development. According to the announcement, the manufacturing firm has a state-of-the-art, FDA-certified pharma production facility located in the United States and managed by veteran professionals with more than five decades of experience. The LOI indicates XPhyto’s interest in evaluating the firm’s ability to produce its oral dissolvable (“ODF”) biosensor products because its facility is capable of thin film medical product formulation, mixing, coating and packaging and has manufactured OTC and FDA-approved products. The LOI identifies key, short-term milestones that the two companies have agreed upon in order to decide future action; those milestones include manufacturing compatibility for XPhyto’s ODF biosensor products, potential EU-GMP certification of the U.S.-based facility, reciprocal import/export opportunities between the United States and Europe, and product R&D collaborations. XPhyto is developing multiple oral health products designed to detect stomatitis, periodontitis and periimplantitis. The company’s first ODF biosensor screening product is for general oral inflammation, which is designed to be a simple, low-cost, and self-administered screening test; the screening test is currently licensed for marketing and sale in Europe.
To view the full press release, visit https://ibn.fm/bObd8
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, as well as diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about the company, visit www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
